Evidence mapPaperPMID 38373412Full record

ReviewGynecologic and obstetric investigation2024

<sc>d</sc>-Chiro-Inositol in Clinical Practice: A Perspective from the Experts Group on Inositol in Basic and Clinical Research (EGOI).

Simona Dinicola, Vittorio Unfer, Christophe O Soulage, Maria Isidora Margarita Yap-Garcia, Arturo Bevilacqua, Salvatore Benvenga, Daniele Barbaro, Artur Wdowiak, Maurizio Nordio, Didier Dewailly and 26 more

Abstract readReview
In one paragraph

Review in Gynecologic and obstetric investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Simona DinicolaThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Vittorio UnferThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Christophe O SoulageThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Maria Isidora Margarita Yap-GarciaThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Arturo BevilacquaThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Salvatore BenvengaThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Daniele BarbaroThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Artur WdowiakThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Maurizio NordioThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Didier DewaillyThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Marialuisa AppetecchiaThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Cesare AragonaThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Maria Salomè Bezerra EspinolaThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Mariano BizzarriThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Pietro CavalliThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Annamaria ColaoThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Rosario D'AnnaThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Mónica Hebe Vazquez-LevinThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Imelda Hernàndez MarinThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Zdravko KamenovThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Antonio Simone LaganàThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Giovanni MonastraThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Mario Montanino OlivaThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Ali Cenk ÖzayThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Basilio PintaudiThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Giuseppina PorcaroThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Olga PustotinaThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Lali PkhaladzeThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Nikos PrapasThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Scott RoseffThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Saghar SalehpourThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Annarita StringaroThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Marat TugushevThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Virginia UnferThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Ivana VucenikThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.
Fabio FacchinettiThe Experts Group on Inositol in Basic and Clinical Research (EGOI), Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background<sc>d</sc>-Chiro-inositol is a natural molecule that, in association with its well-studied isomer myo-inositol, may play a role in treating various metabolic and gynecological disorders.

objectivesThis perspective seeks to explore the mechanisms and functions of <sc>d</sc>-chiro-inositol, laying the foundations to discuss its use in clinical practice, across dysmetabolism, obesity, and hormonal dysregulation.

methodsA narrative review of all the relevant papers known to the authors was conducted. OUTCOME: <sc>d</sc>-Chiro-inositol acts through a variety of mechanisms, acting as an insulin sensitizer, inhibiting the transcription of aromatase, in addition to modulating white adipose tissue/brown adipose tissue transdifferentiation. These different modes of action have potential applications in a variety of therapeutic fields, including PCOS, dysmetabolism, obesity, hypoestrogenic/hyperandrogenic disorders, and bone health.

conclusions<sc>d</sc>-Chiro-inositol mode of action has been studied in detail in recent years, resulting in a clear differentiation between <sc>d</sc>-chiro-inositol and its isomer myo-inositol. The insulin-sensitizing activities of <sc>d</sc>-chiro-inositol are well understood; however, its potential applications in other fields, in particular obesity and hyperestrogenic/hypoandrogenic disorders in men and women, represent promising avenues of research that require further clinical study.

Indexed as

InositolInsulin ResistanceObesityPolycystic Ovary SyndromeAndrogensAromataseEstrogensHumansAndrogensAromataseEstrogensInositolAndrogensAromataseEstrogensInsulin resistance<sc>d</sc>-Chiro-inositol

Identifiers

PMID38373412
PMCPMC11309080

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.